Sep 14Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease
Jun 20Anavex Life Sciences to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
May 2Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023
Apr 25Anavex Life Sciences to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
Dec 14, 2022Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Dec 2, 2022Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Nov 28, 2022Anavex Life Sciences Reports Fiscal 2022 Year End Financial Results and Provides Business Update
Sep 21, 2022Anavex Life Sciences new U.S. Patent ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders
Aug 23, 2022Anavex Reports Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation in AD
Aug 2, 2022Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Jul 29, 2021Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits
Jun 14, 2021Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)